The London conference on neglected tropical diseases (NTDs) held in January was a seminal moment in the global fight against a group of diseases which are often overshadowed in the global health agenda by HIV, malaria and TB.
Sabin President Dr. Peter Hotez's latest editorial, titled “Campaign Spending: What Else Can $2 Billion Buy?” was recently published in the Huffington Post. The editorial discusses how the amount of money spent on this year’s presidential campaign could have also been used to treat and control NTDs in various regions around the world.
See the original article in the Huffington Post here.
The open-access journal, PLoS NTDs, celebrated its fifth anniversary. To commemorate this great achievement, the journal compiled editorials and research papers published over the last five years to create a collection, called “The Geopolitics of NTDs.”
The collection focuses on the geographic distribution of NTDs by region to highlight the key differences as well as similarities between the diseases in different areas around the world.
October 11, 2012 | Financial Times
The Financial Times special report “Combating Neglected Diseases” contains in-depth stories and interviews featuring several of Sabin’s key programs, including Sabin Vaccine Development, the Global Network for Neglected Tropical Diseases and the Dengue Vaccine Initiative.
Read the full report here.
The Schistosomiasis Vaccine Initiative was launched in 2008 through funding from Mr. Morton Hyman and the Blavatnik Family Foundation. In collaboration with researchers at James Cook University and The George Washington University, a promising antigen, Sm-TSP-2, was selected for development.
Schistosomiasis is a parasite carried by snails and transmitted through contact with contaminated fresh water sources such as lakes, ponds, rivers and dams. Schistosomiasis infection is readily transmissible for those who come in frequent contact with contaminated water – particularly children who wade or play in water and women conducting domestic chores.
In collaboration with researchers at the James Cook University and The George Washington University, a promising new antigen, Sm-TSP-2 (Schistosoma mansoni Tetraspanin-2), was selected for development as a schistosomiasis vaccine. Then at Texas Children's Hospital and Baylor College of Medicine, Sabin and its partners developed the process for manufacture of the vaccine under cGMP, and was followed by technology transfer to Sabin's manufacturing partner, Aeras.